Nomita Kim, MD
Family Medicine · Austin, TXNPI 1013070754
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,686 of the $6,379 with a category attached, or 73.5%. 39 manufacturers reported payments, led by Eli Lilly at 30.8% of the total. Reporting peaked in 2024 at $2,799 and has fallen 75.7% since, to $680 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Lilly USA, LLC$775
- Abbott$543
- Amgen$462
- AbbVie$308
- GSK$228
- plus $2K from 33 others
Across 480 payments — averaging $7024.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.4M
- Modernatx, Inc.$1.1M
- Boehringer Ingelheim International GmbH$329K
- Bristol Myers Squibb$100K
- Amgen$85K
- AstraZeneca$69K
- plus $272K from 10 others
What the payments were for
- Travel & lodging$1,64626%
- Food & beverage$4,68673%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 16 | $1,962 |
| Lilly USA, LLC | 49 | $775 |
| Abbott | 24 | $543 |
| Amgen | 21 | $462 |
| AbbVie(2 entities) | 12 | $308 |
| GSK | 14 | $228 |
| Esperion Therapeutics, Inc. | 7 | $214 |
| Boehringer Ingelheim | 8 | $208 |
| Pfizer | 9 | $185 |
| Axsome Therapeutics, Inc. | 4 | $175 |
| Novo Nordisk | 8 | $150 |
| Biogen | 2 | $118 |
| Merck | 4 | $118 |
| Vifor Pharma, Inc. | 1 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $110 |
| Impulse Dynamics (USA) Inc. | 1 | $80 |
| AstraZeneca | 4 | $56 |
| Convatec Inc. | 2 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Bayer | 2 | $46 |
| Dexcom, Inc. | 2 | $39 |
| Medtronic | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $35 |
| Corcept Therapeutics | 2 | $33 |
| Astellas Pharma US Inc | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Bausch Health US, LLC | 1 | $24 |
| Romark Laboratories, LC | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Gilead | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Novartis | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,379 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 77 | $104,031 |
| JardianceEmpagliflozin | 91 | $97,448 |
| OzempicSemaglutide | 52 | $80,871 |
| FarxigaDapagliflozin Propanediol | 36 | $28,341 |
| JanuviaSitagliptin Phosphate | 23 | $27,398 |
| TrulicityDulaglutide | 11 | $20,442 |
| Repatha SureclickEvolocumab | 13 | $18,973 |
| KerendiaFinerenone | 24 | $18,325 |
| EliquisApixaban | 18 | $15,819 |
| Fluticasone Propionate | 58 | $10,490 |
| Atorvastatin Calcium | 323 | $2,928 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,571 |
| Rosuvastatin Calcium | 215 | $2,507 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,138 |
| Levothyroxine Sodium | 175 | $2,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $775 | $124,47388 claims |
| Boehringer IngelheimJardiance | $208 | $97,44891 claims |
| Novo NordiskOzempic | $150 | $80,87152 claims |
| AstraZenecaFarxiga | $56 | $28,34136 claims |
| MerckJanuvia | $118 | $27,39823 claims |
| BayerKerendia | $46 | $18,32524 claims |
| PfizerEliquis | $185 | $15,81918 claims |
| AbbVieSynthroid | $308 | $1,10218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- Cynthia BrinsonAustin$402K
- David WrightAustin$124K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.